About US
Contact us
-
Scott Gottlieb resigns as FDA commissionerScott Gottlieb has announced his resignation from the position of commissioner of the US Food and Drug Administration (FDA). Gottlieb cited his weekly commute from Connecticut to Washington as his ma2019/3/6
-
Janssen secures FDA approval for new depression drug SHAREJohnson & Johnson subsidiary Janssen Pharmaceutical has obtained approval from the US Food and Drug Administration (FDA) for its Spravato (esketamine) nasal spray to treat adults with major depre2019/3/5
-
Pfizer licences type 1 diabetes therapy from AnTolRxPfizer has licensed an immunotherapy treatment intended to combat Type 1 diabetes from US-based biotechnology firm AnToIRx. To acquire the rights, Pfizer exercised an option under an existing agreeme2019/3/5
-
CEPI joins forces with CureVac for vaccine printing platformThe Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with German biopharmaceutical firm CureVac that is developing a transportable automated messenger RNA (mRNA) vaccine printing2019/3/4
-
BMS faces shareholder opposition to $74bn Celgene acquisitionBristol-Myers Squibb’s (BMS) proposed $74bn acquisition of Celgene is under threat as its two main shareholders, Wellington Management and Starboard Value, are opposing the deal. Wellington Managemen2019/3/4
-
Maze Therapeutics raises $191m to support genetic researchMaze Therapeutics, a start-up with focus on translating genetic insights into new medicines, has been launched operations in the by Third Rock Ventures. Alongside other investors including RCH Ventur2019/3/1
-
Sarepta exercises option to acquire Myonexus for $165mUS rare disease gene therapy company Sarepta has exercised its right from an exclusive partnership to acquire another gene therapy company Myonexus. Sarepta will pay $165m to Myonexus shareholders af2019/3/1
-
AstraZeneca, Merck's Lynparza posts pancreatic cancer win in another PARP-class firstAstraZeneca and Merck’s Lynparza has already led its class into two disease areas, and now it’s looking to make it three. Tuesday, the companies said their PARP inhibitor hadtoppedplacebo at staving2019/2/28
-
Former Novartis executive wins $1.5M in whistleblower retaliation lawsuitMore than four years after a former executive at Novartis sued thedrugmakerclaiming she lost her job for suggesting a drug study might be a type of kickback, a jury has sided in her favor. Min Amy Gu2019/2/28
-
Ipsen to buy Clementia Pharmaceuticals in $1bn dealFrench pharmaceutical company Ipsen has agreed to acquire Canada-based Clementia Pharmaceuticals for an initial aggregate cash consideration of $1.04bn to boost its rare disease portfolio. The terms2019/2/27